Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioventus Inc

Bioventus Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
11.7813 USD 0.84 ( 7.64%)
Last update at 2026-11-04T15:10:00Z
VOLUME
116072
Market Cap
887.97M
P/E
16.88

Momentum Score

…

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.17
Low
11.81
High
52 Week Price Range
6.25
Low
15.89
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
10.95
Dividend Yield
-
Revenue TTM
581.85M
Revenue Per Share
8.65
Gross Profit TTM
399.45M
Debt / Equity
1.69
ROE
25.68%
Net Debt
260.11M
ROCE
11.19%
Diluted EPS TTM
0.77

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 25.71M -49.13M -121.11M -263.90M 7.62M
Minority interest -4.54M 10.29M 50.78M 54.69M -9.79M
Net income 22.73M -33.54M -156.23M -213.39M 9.59M
Selling general administrative 314.03M 322.67M 300.03M 33.92M 255.08M
Selling and marketing expenses - 4.42M 3.85M 42.90M -
Gross profit 382.43M 388.23M 328.19M 331.08M 302.71M
Reconciled depreciation 47.01M 49.55M 73.25M 66.80M 34.88M
Ebit 58.55M -10.33M -80.44M -35.68M 17.72M
Ebitda 105.56M 39.22M -23.07M 31.13M 52.60M
Depreciation and amortization 47.01M 49.55M 57.37M 66.80M 34.88M
Non operating income net other - - - - -3.33M
Operating income 58.55M -11.98M -81.72M -35.68M 17.72M
Other operating expenses 509.54M 585.26M 594.07M 560.74M 409.85M
Interest expense 26.49M 38.79M 40.68M 25.80M 1.11M
Tax provision -1.56M -5.29M -16.26M -50.51M -1.97M
Net interest income -26.49M -38.79M -51.56M -25.80M -1.11M
Non recurring - - - - 8.16M
Income tax expense -1.56M -5.29M 0.09M -50.51M -1.97M
Total revenue 568.09M 573.28M 512.35M 512.12M 430.90M
Total operating expenses 323.88M 400.20M 409.92M 379.70M 281.65M
Cost of revenue 185.66M 185.05M 184.15M 181.04M 128.19M
Total other income expense net -32.84M -37.15M -39.39M -228.22M -10.10M
Net income from continuing ops 27.27M -43.83M -203.76M -213.39M 9.59M
Net income applicable to common shares - - - - 19.38M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 683.56M 727.96M 810.91M 1372.65M 1225.86M
Intangible assets 368.42M 404.73M 482.35M 1038.72M 695.19M
Other current assets 11.06M 14.16M 16.66M 18.68M 27.24M
Total liab 455.11M 542.35M 589.79M 1032.32M 692.07M
Total stockholder equity 184.10M 147.94M 173.59M 316.58M 458.92M
Deferred long term liab - - - - 133.52M
Other current liab 130.24M 155.50M 115.81M 233.41M 3.56M
Common stock 0.08M 0.08M 0.08M 0.08M 0.07M
Capital stock 0.08M 0.08M 0.08M 0.08M 0.07M
Retained earnings -334.93M -355.08M -321.54M -165.31M -6.60M
Other liab - - - - 171.57M
Good will 7.46M 7.46M 7.46M 13.76M 147.62M
Other assets - - - - 50.48M
Cash 51.24M 41.58M 36.96M 31.81M 43.93M
Total current liabilities 160.38M 210.40M 175.50M 304.02M 180.86M
Current deferred revenue - - 4.75M - 142.35M
Net debt 260.11M 294.05M 372.51M 386.25M 313.75M
Short term debt 19.21M 27.34M 31.91M 33.06M 18.04M
Short long term debt 15.00M 27.34M 27.85M 33.06M 18.04M
Short long term debt total 311.35M 335.63M 409.48M 418.07M 357.68M
Other stockholder equity 520.85M 505.51M 494.25M 481.92M 465.27M
Property plant equipment - - - - 22.98M
Total current assets 272.84M 275.61M 268.00M 272.57M 263.10M
Long term investments - - - 2.64M 29.29M
Net tangible assets - - - - -383.89M
Net receivables 128.30M 127.39M 123.05M 136.65M 124.96M
Long term debt 278.95M 308.29M 367.00M 385.01M 339.64M
Inventory 82.24M 92.47M 91.33M 85.41M 61.69M
Accounts payable 10.93M 23.69M 23.04M 37.55M 16.91M
Noncontrolling interest in consolidated entity - - - - 74.86M
Accumulated other comprehensive income -1.90M -2.57M 0.79M -0.11M 0.18M
Common stock total equity - - - - 0.07M
Retained earnings total equity - - - - -6.60M
Non currrent assets other 2.29M 1.89M 3.14M -154.00M 50.00M
Non current assets total 410.72M 452.35M 542.91M 1100.07M 962.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 22.96M 12.99M -116.44M -13.52M
Change to liabilities - - - - 18.21M
Total cashflows from investing activities -3.25M 22.96M 15.81M - -283.76M
Net borrowings -42.91M -59.58M -23.26M - 166.20M
Total cash from financing activities -61.44M -54.58M -26.65M 62.08M 273.37M
Change to operating activities - - - - -13.28M
Net income 22.73M -0.32M -121.20M -213.39M 9.59M
Change in cash 9.66M 4.62M 5.13M -67.38M 12.37M
Begin period cash flow 41.58M 36.96M 31.84M 99.21M 86.84M
End period cash flow 51.24M 41.58M 36.96M 31.84M 99.21M
Total cash from operating activities 73.98M 38.80M 15.34M -13.54M 22.99M
Issuance of capital stock 2.07M 2.44M 1.70M 5.82M 109.41M
Depreciation 47.01M 49.55M 57.37M 66.80M 34.88M
Other cashflows from investing activities -3.25M 23.97M -11.51M - -262.87M
Dividends paid - - - 0.00M -0.37M
Change to inventory 8.57M -16.43M -5.99M -18.62M 3.18M
Change to account receivables -0.92M -10.67M 10.05M -18.02M -20.05M
Sale purchase of stock - - - - 277.45M
Other cashflows from financing activities -20.61M 2.56M -4.17M 101.29M -1.88M
Change to netincome - - - - 11.89M
Capital expenditures 2.56M 1.01M 7.36M 11.52M 7.37M
Change receivables - - - - -20.05M
Cash flows other operating - - - - -25.12M
Cash and cash equivalents changes - - - - 12.60M
Change in working capital -13.84M -11.78M -3.18M -14.53M -13.28M
Stock based compensation 12.67M 10.06M 2.72M 17.59M -4.51M
Other non cash items 87.82M -3.33M 82.01M 182.79M 6.08M
Free cash flow 71.41M 37.79M 7.98M -25.06M 15.62M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BVS
Bioventus Inc		 0.84
7.64%		 11.78 16.88 14.31 1.53 3.94 1.92 10.78
ABT
Abbott Laboratories		 3.15
2.88%		 112.55 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 4.05
4.10%		 102.93 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 18.89
6.08%		 329.44 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 48.37 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Bioventus Inc

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

4721 Emperor Boulevard, Durham, NC, United States, 27703

919 474 6700

https://www.bioventus.com

950

Name Title Year Born
Mr. Kenneth M. Reali CEO & Director 1966
Mr. Mark Singleton Sr. VP, CFO & Principal Accounting Officer 1969
Mr. Anthony James VP of Operations and Quality NA
Mr. Miguel O. Beltran-Delgado Sr. VP of Operations NA
Ms. Alessandraa Pavesio Sr. VP & Chief Science Officer 1967
Mr. David Crawford VP of Investor Relations & Treasurer NA
Mr. Anthony D'Adamio Sr. VP, Gen. Counsel & Corp. Sec. 1961
Ms. Katrina J. Church Sr. VP & Chief Compliance Officer 1962
Mr. Jeff Welch VP of Bus. Devel. NA
Mr. Christopher K. Yamamoto Sr. VP of Corp. Devel. & Strategy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…